Beetham Thomas W. 4
4 · Viridian Therapeutics, Inc.\DE · Filed Nov 1, 2023
Insider Transaction Report
Form 4
Beetham Thomas W.
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-10-30+474,400→ 474,400 totalExercise: $13.02Exp: 2023-10-30→ Common Stock (474,400 underlying)
Footnotes (1)
- [F1]The option vests as to 25% on October 30, 2024 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date.